ArticleMolecular oncology2026
In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor recurrence after local tumor ablation, including high dose rate brachytherapy (HDR-BT), represents a substantial challenge in hepatocellular carcinoma (HCC) treatment. This study aimed to investigate whether induced factors that appear in patient serum after HDR-BT alter HCC growth in vitro, and whether this correlates with outcome. In total, 23 HCC patients [Barcelona clinic liver cancer (BCLC) stage A or B] were treated by HDR-BT (1 × 15 Gy) and classified as responders in case of no progression within 6 months and no diffuse systemic progression within 2 years (n = 12), or nonresponders with recurrence within 6 months and/or diffuse systemic tumor progression or extrahepatic disease within 2 years (n = 11). Patient serum was obtained at baseline and 48 h postprocedure. Two hepatoma cell lines (Huh7, HepG2) were incubated for 72 h in the presence of 20% serum. BrdU incorporation was assessed for serum incubation at baseline and 48 h post-HDR-BT. BrdU incorporation post-HDR-BT compared to baseline was significantly elevated in nonresponders compared to responders for both Huh7 and HepG2. Likewise, confirmatory Cyclin E studies revealed different induction kinetics between a subset of representative responders and nonresponders in HepG2. Time to systemic progression (TTSP) in patients with increased BrdU incorporation was significantly shorter compared to patients with decreased BrdU incorporation after serum incubation. These data indicate that poor outcome following HDR-BT is associated with increased measurable proliferation parameters of hepatoma cell lines in vitro after exposure to patient serum, offering insights into post-treatment tumor biology and a potential biomarker of clinical outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.